/
RSS Feed
LOS ANGELES—A more powerful back-up drug for patients intolerant to statins was announced at the American Heart Association 2012 Scientific Sessions. A monoclonal antibody called: AMG 145 against a protein found to regulate LDL receptor activity — the PCSK 9 protein — has been tested in the phase II GAUSS study in comparison with ezetimibe, a standard but less powerful alternative to statins. Sarah Maxwell heard from investigator Dr Evan Stein, from the Metabolic and Atherosclerosis Research Center in Cincinnati and from commenting expert Dr Peter Wilson of Emory University in Atlanta.
LISTEN
[audio:https://www.audiomedica.com/podcasting/aha/121116EvanSteinPeterWilsonGAUSSPODCASTLoRes.mp3]
